Oral H1N1 influenza vaccine: Phase I data

A double-blind, U.S. Phase I trial in 24 healthy volunteers ages 18-49 showed that a single dose of Vaxart’s oral H1N1 influenza vaccine led to a 4-fold increase in hemagglutination inhibition (HAI) a...